证券代码：300841 证券简称：康华生物 公告编号：2025-019 成都康华生物制品股份有限公司 关于续聘2025年度审计机构的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚假 记载、误导性陈述或重大遗漏。 成都康华生物制品股份有限公司（以下简称"公司"）于2025年4月17日召开 第三届董事会第六次会议和第三届监事会第六次会议，审议通过了《关于续聘公 司2025年度审计机构的议案》，同意公司续聘立信会计师事务所（特殊普通合伙） 为公司2025年度审计机构。本次续聘符合《国有企业、上市公司选聘会计师事务 所管理办法》的相关规定。本事项尚需提交公司2024年年度股东大会审议。现将 具体情况公告如下： 一、 拟续聘会计师事务所的基本信息 （一）机构信息 1、基本信息 名称：立信会计师事务所（特殊普通合伙） 统一社会信用代码：91310101568093764U 成立日期：2011年01月24日 类型：特殊普通合伙企业 注册地址：上海市黄浦区南京东路61号四楼 注册资本：15900万元人民币 2、投资者保护能力 截至2024年末，立信已提取职业风险基金1.66亿元，购买的职业保险累计赔 ...

成都康华生物制品股份有限公司 一、 2024 年度财务决算报告 2024 年度财务决算及 2025 年度财务预算报告 成都康华生物制品股份有限公司（以下简称"公司"）2024 年度财务报表已经 立信会计师事务所（特殊普通合伙）审计，出具了标准无保留意见的审计报告。 会计师认为：公司财务报表在所有重大方面按照企业会计准则的规定编制，公允 反映了公司 2024 年 12 月 31 日的合并及母公司财务状况以及 2024 年度的合并 及母公司的经营成果和现金流量。 2024 年度，实现营业收入 143,187.66 万元，同比降低 9.23%；实现归属于上 市公司股东的净利润 39,865.19 万元，同比降低 21.71%；实现归属于上市公司股 东的扣除非经常性损益的净利润 45,749.50 万元，同比降低 15.75%。现将 2024 年度财务决算（合并口径）的相关情况报告如下： (一)主要资产情况 1、报告期内，应收账款较期初降低 7.91%，主要是公司回款额大于销售额 所致； 2、报告期内，货币资金较期初降低 3.66%，主要是公司分配现金股利及回 购股份增加所致； 3、报告期内，固定资产较期初增长 12 ...

Financial Performance - The company's revenue for Q1 2025 was ¥137,942,758.51, a decrease of 55.70% compared to ¥311,367,042.84 in the same period last year[7]. - Net profit attributable to shareholders was ¥20,708,594.70, down 86.15% from ¥149,466,993.99 year-on-year[7]. - Basic and diluted earnings per share were both ¥0.1594, representing an 85.77% decrease from ¥1.1204 in the same period last year[7]. - Total operating revenue for the current period is ¥137,942,758.51, a decrease of 55.7% compared to ¥311,367,042.84 in the previous period[27]. - Net profit for the current period is ¥20,708,594.70, compared to ¥149,466,993.99 in the previous period, reflecting a significant decline[28]. - Total comprehensive income attributable to the parent company was CNY 20,708,594.70, compared to CNY 149,466,993.99 in the previous period, indicating a significant decrease[29]. Cash Flow and Assets - The net cash flow from operating activities was -¥16,686,433.97, a decline of 116.93% compared to ¥98,589,924.72 in the previous year[14]. - Current assets total ¥2,354,274,529.10, down from ¥2,488,001,102.09 at the beginning of the period, indicating a decrease of 5.4%[24]. - Cash and cash equivalents decreased to ¥931,949,521.90 from ¥1,001,326,623.71, a decline of 6.9%[23]. - The ending balance of cash and cash equivalents was CNY 681,949,521.90, down from CNY 1,007,828,965.84 in the previous period[32]. - The company reported a financial expense of -¥459,538.23, an improvement compared to -¥2,204,660.06 in the previous period[28]. Liabilities and Shareholder Information - Total liabilities amount to ¥415,450,340.07, a reduction from ¥580,073,577.69 in the previous period, representing a decrease of 28.5%[25]. - Total number of common shareholders at the end of the reporting period is 21,584[17]. - The largest shareholder, Aokang Group Co., Ltd., holds 12.26% of shares, totaling 16,305,468 shares, with 10,730,000 shares pledged[17]. - Wang Zhentao, a significant shareholder, owns 10.53% of shares, amounting to 14,004,687 shares, with 13,487,500 shares pledged[17]. - The top 10 shareholders collectively hold significant stakes, with the largest three shareholders accounting for 29.87% of total shares[17]. Operating Costs and Revenue Decline - The company reported a 32.75% decline in revenue after excluding the previous year's one-time overseas authorization income of ¥106,240,500.00[7]. - The company's operating costs decreased by 36.97% to ¥7,686,111.19 due to reduced vaccine sales[12]. - Total operating costs for the current period are ¥112,232,733.05, down 16.8% from ¥134,855,630.79 in the previous period[27]. Changes in Assets - Total assets at the end of the reporting period were ¥3,883,667,631.05, down 3.57% from ¥4,027,582,273.97 at the end of the previous year[7]. - Non-current assets total ¥1,529,393,101.95, slightly down from ¥1,539,581,171.88 at the beginning of the period[24]. - Accounts receivable decreased to ¥1,211,775,915.46 from ¥1,298,879,167.25, a reduction of 6.7%[23]. - Inventory increased to ¥188,083,939.24 from ¥176,882,114.20, an increase of 6.7%[23]. Share Repurchase and Restricted Shares - The company has a total of 3,000,000 shares repurchased, representing 2.26% of total share capital, not included in the top 10 shareholders[18]. - The total number of restricted shares at the beginning of the period was 12,454,048, with 1,401,515 shares released during the period[21]. - The company has a total of 11,052,533 restricted shares remaining at the end of the reporting period[21]. - Wang Zhentao's restricted shares remain unchanged at 10,503,515 due to lock-up agreements[20]. Investment Activities - Cash inflow from investment activities was CNY 260,116,367.66, compared to CNY 50,000,000.00 in the previous period, showing a substantial increase[32]. - Cash outflow from investment activities totaled CNY 331,760,357.62, up from CNY 135,789,842.57 in the previous period[32]. Other Observations - The company experienced a 79.68% decline in fair value gains to ¥106,031.53, attributed to changes in the fair value of its equity investments[12]. - Other current assets increased by 4427.75% to ¥9,089,810.09, primarily due to withholding of corporate income tax from overseas authorization[15]. - The company reported a 68.23% decrease in payable employee compensation to ¥10,600,668.63, reflecting the distribution of 2024 annual salaries[15]. - The company did not report any net profit from merged entities during the current or previous periods[29]. - There are no new strategies or significant market expansions mentioned in the provided documents[22].

Revenue and Financial Performance - The company's operating revenue for 2024 was ¥1,431,876,598, a decrease of 9.23% compared to ¥1,577,395,401 in 2023[25]. - The net profit attributable to shareholders for 2024 was ¥398,651,923, down 21.71% from ¥509,215,965 in 2023[25]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥457,495,046, a decrease of 15.75% from ¥543,046,767 in 2023[25]. - The total assets at the end of 2024 were ¥4,027,582,274, a decline of 4.32% from ¥4,209,268,312 in 2023[25]. - The basic earnings per share for 2024 was ¥3.0279, down 20.47% from ¥3.8073 in 2023[25]. - The weighted average return on equity for 2024 was 11.64%, down from 15.29% in 2023, a decrease of 3.65%[25]. - The net cash flow from operating activities for 2024 was ¥572,241,897, a slight decrease of 0.30% from ¥573,983,334 in 2023[25]. - The company reported a negative net profit of ¥7,250,303 in the fourth quarter of 2024, primarily due to losses from fair value changes of associated companies[27]. - The company received government subsidies amounting to ¥2,699,577 in 2024, compared to ¥851,890 in 2023[31]. - The company reported a total non-recurring loss of ¥58,843,123 in 2024, compared to a loss of ¥33,830,802 in 2023[32]. Product Development and Innovation - The company emphasizes ongoing product innovation and process improvement to enhance product safety and maintain competitive advantages in the market[8]. - The company is focused on strengthening its R&D team and mechanisms to mitigate development risks across multiple research directions[6]. - The company has established multiple vaccine research and development platforms and has participated in national and provincial scientific projects, enhancing its innovation capabilities[50]. - The company has developed a freeze-dried rabies vaccine using human diploid cells, which has improved virus yield and reduced production costs, while ensuring safety and immunogenicity[52]. - The company is developing a six-valent norovirus vaccine, with clinical trials approved in Australia and the US, expected to enhance market competitiveness[71]. - The company is developing a vaccine for the prevention of meningitis caused by ACYW135 group bacteria, with clinical trials planned after completing preclinical research[72]. - The company has seven major R&D projects underway, with the six-valent norovirus vaccine expected to enter clinical trials in 2024[43]. Market and Industry Trends - The global vaccine market size in 2023 is approximately 7 billion doses, valued at $77 billion, accounting for about 5% of the total global pharmaceutical market revenue[35]. - Major vaccine products such as HPV, pneumococcal, influenza, and shingles vaccines account for 70% of global vaccine sales, with expectations for continued growth in vaccination accessibility and public awareness post-pandemic[35]. - The global human vaccine market is projected to reach approximately $83.1 billion by 2025 and $131 billion by 2030, driven by increased health awareness and demand for infectious disease prevention[35]. - China's vaccine industry is transitioning from "scale expansion" to "innovation-driven" strategies, with a focus on mRNA, recombinant protein, and viral vector technologies[36]. - The number of domestically produced vaccines pre-certified by WHO is expected to increase to 18 by 2024, indicating significant improvement in international quality recognition[37]. - In 2023, 68 countries reported at least one vaccine shortage, highlighting a substantial global supply-demand gap in the vaccine market[37]. Corporate Governance and Compliance - The company has a governance structure that complies with relevant laws and regulations, ensuring equal rights for all shareholders[105]. - The board consists of 7 members, including 3 independent directors, ensuring a diverse skill set[106]. - The company held 10 board meetings during the reporting period, all conducted in accordance with legal requirements[106]. - The company has an independent internal audit department reporting to the audit committee, enhancing financial oversight[107]. - The company maintains transparency in information disclosure, ensuring timely and accurate communication with investors[109]. - The company operates independently from its controlling shareholders in terms of assets, personnel, and financial management[110]. Environmental Responsibility - The company obtained a revised pollutant discharge permit on March 20, 2023, with a validity of five years[158]. - The company has implemented a wastewater treatment process that includes multiple stages, ensuring compliance with discharge standards[160]. - The company has established an emergency response plan for environmental incidents, which was completed and filed with the local environmental bureau on January 28, 2023[160]. - The company adheres to various environmental protection laws and standards, including the Environmental Protection Law and the Air Pollution Prevention and Control Law[158]. - The company has no instances of exceeding pollutant discharge limits during the reporting period[159]. - The company utilizes advanced technologies for waste gas treatment, including ultraviolet light purification and activated carbon adsorption[160]. Shareholder Engagement and Dividends - The company plans to distribute a cash dividend of 10 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[8]. - The company plans to distribute a cash dividend of 20 RMB per 10 shares, totaling 129,946,899 RMB for the 2023 fiscal year[145]. - The total cash dividend, including other methods, amounts to 329,944,525.19 RMB, representing 100% of the total profit distribution[145]. - The company has established a competitive and fair compensation system to align employee income with business performance[139]. Risk Management - The company acknowledges risks associated with product development and sales, particularly in the context of long R&D cycles and external environmental changes[6]. - The R&D risk in the vaccine sector is high, with the need for extensive laboratory research, preclinical studies, and clinical trials before obtaining registration[38]. - The cycle from vaccine development to usage is long, divided into five stages: R&D, registration, production, distribution, and usage[38]. Marketing and Sales Strategy - The company is enhancing its brand and channel construction through various marketing strategies, including public education and participation in industry events[46]. - The company is focused on integrating internal and external marketing resources to optimize its sales management system and improve market coverage[47]. - The marketing strategy will be strengthened by training specialized sales personnel and optimizing the marketing management system to enhance brand influence and market coverage[98]. Employee Development and Corporate Culture - The company has established a robust talent development system to enhance employee skills and retain core talent, supporting long-term growth[56]. - The company emphasizes a culture of integrity, efficiency, innovation, and responsibility in its training and development initiatives[141]. - The training program includes both internal and external training, focusing on compliance and professional skills enhancement[141][142].

成都康华生物制品股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 证券代码：300841 证券简称: 康华生物 公告编号：2025-026 成都康华生物制品股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召 开了第三届董事会第六次会议，审议通过了《关于召开公司 2024 年年度股东大 会的议案》，决定于 2025 年 5 月 9 日召开 2024 年年度股东大会（以下简称"会 议"或"股东大会"），现将会议的有关事项通知如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2024 年年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召集、召开符合有关法律、 行政法规、部门规章、其他规范性文件及《公司章程》的有关规定。 4、会议召开的日期与时间 （1）现场会议召开时间：2025 年 5 月 9 日（星期五）下午 14:30 （2）网络投票时间：2025 年 5 月 9 日。其中，通过深圳证券交易所交易系 统进行网络投票的具体时间为：2025 年 ...

成都康华生物制品股份有限公司 第三届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都康华生物制品股份有限公司（以下简称"公司"）第三届监事会第六次会 议通知已于2025年4月7日以专人送达、邮件等方式向全体监事发出。会议于2025 年4月17日在四川省成都市龙泉驿区北京路182号公司会议室以现场会议的方式 召开。会议由监事会主席吴淑青女士召集并主持，会议应出席监事3名，实际出 席监事3名。本次会议的召集、召开程序符合《中华人民共和国公司法》等法律、 法规、规范性文件和《成都康华生物制品股份有限公司章程》（以下简称"《公 司章程》"）、《成都康华生物制品股份有限公司监事会议事规则》的有关规定， 会议合法、有效。 二、监事会会议审议情况 证券代码：300841 证券简称：康华生物 公告编号：2025-009 公司编制和审核2024年年度报告及其摘要的程序符合法律、行政法规、中国 证监会和深圳证券交易所的相关规定，报告内容真实、准确、完整，不存在虚假 记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯 ...

2024 年，公司董事会严格按照法律法规及《公司章程》的相关规定，切实 履行股东大会赋予的董事会职责，勤勉尽责地开展各项工作，促进公司持续、健 康、稳定的发展。 证券代码：300841 证券简称：康华生物 公告编号：2025-008 成都康华生物制品股份有限公司 第三届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 成都康华生物制品股份有限公司（以下简称"公司"）第三届董事会第六次 会议通知于2025年4月7日以电邮和专人通知的方式向全体董事和监事发出，会议 于2025年4月17日在四川省成都市龙泉驿区北京路182号公司会议室以现场会议 的方式召开。本次会议由董事长王振滔先生召集并主持，会议应出席董事7人， 实际出席董事7人，公司监事、高级管理人员列席了本次会议。本次会议的召集 和召开程序符合《中华人民共和国公司法》（以下简称"《公司法》"）、《成 都康华生物制品股份有限公司章程》（以下简称"《公司章程》"）等有关规定， 会议合法、有效。 二、 董事会会议审议情况 （一）审议通过《关于公司 2024 年度董事 ...

一、审议程序 成都康华生物制品股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召 开第三届董事会第六次会议及第三届监事会第六次会议，审议通过了《关于公司 2024 年度利润分配预案的议案》，本预案尚需提交公司 2024 年年度股东大会审 议。 二、2024 年度利润分配预案 经立信会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属于上 市公司股东的净利润 398,651,923.09 元，母公司实现净利润 461,062,810.49 元。 按照《公司法》《公司章程》的规定，公司法定盈余公积金累计额已达到注册资 本的 50%以上，公司 2024 年不再提取法定盈余公积金。截止 2024 年 12 月 31 日，经审计合并口径可供股东分配的利润为 2,389,084,799.27 元，母公司口径可 供股东分配的利润为 2,255,366,890.56 元。根据《深圳证券交易所上市公司自律 监管指引第 2 号—创业板上市公司规范运作》规定，按照合并报表、母公司报表 中可供分配利润孰低原则，2024 年度可供股东分配的利润为 2,255,366,890.56 元。 经综合考虑公司财务状 ...

证券代码：300841 证券简称：康华生物 公告编号：2025-007 成都康华生物制品股份有限公司 关于实际控制人之一致行动人部分股份解除质押和质押 的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏,并就其保证承担个别和连带的责任。 成都康华生物制品股份有限公司（以下简称"公司"）于近日接到控股股东、 实际控制人王振滔先生之一致行动人奥康集团有限公司（以下简称"奥康集团"） 的通知，获悉奥康集团将其持有的公司部分股份办理了解除质押和质押业务，具 体情况如下： 二、 本次股东股份质押的基本情况 | | 是否为 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 | | | 占公 | | 是否 | | | | | | 股东 | 东或第 | 本次质押 | 占其所 | 司总 | 是否 | 为补 | 质押起始 | 质押到 | | 质押 | | | 一大股 | 股份数量 | 持股份 | | 为限 | | | | 质权人 | | ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏,并就其保证承担个别和连带的责任。 成都康华生物制品股份有限公司（以下简称"公司"）于近日接到控股股东、 实际控制人王振滔先生之一致行动人奥康集团有限公司（以下简称"奥康集团"） 的通知，获悉奥康集团将其持有的公司部分股份办理了解除质押和质押业务，具 体情况如下： 二、 本次股东股份质押的基本情况 | | 是否为 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 | | | 占公 | | 是否 | | | | | | 股东 | 东或第 | 本次质押 | 占其所 | 司总 | 是否 | 为补 | 质押起始 | 质押到 | | 质押 | | | 一大股 | 股份数量 | 持股份 | | 为限 | | | | 质权人 | | | 名称 | | | | 股本 | | 充质 | 日 | 期日 | | 用途 | | | 东及其 | （股） | 比例 | | 售股 | | | | | | | ...